Idolazzi, L.
El Ghoch, M.
Dalle Grave, R.
Bazzani, P. V.
Calugi, S.
Fassio, S.
Caimmi, C.
Viapiana, O.
Bertoldo, F.
Braga, V.
Rossini, M.
Gatti, D.
Article History
Received: 30 June 2016
Accepted: 17 October 2016
First Online: 27 October 2016
Change Date: 29 November 2019
Change Type: Correction
Change Details: Unfortunately, the sixth author name was incorrectly spelled as ���S. Fassio��� instead of ���A. Fassio��� in the original publication.
Compliance with ethical standards
:
: Viapiana O has received speaking fees from Abiogen, Amgen, Merck Sharp & Dohme Corp. Idolazzi L has received speaking fees from Eli Lilly, UCB, Abbvie, Novartis. Fassio A declares he has no conflict of interests. Caimmi C declares he has no conflict of interests. Rossini M has received speaking and consulting fees from Abiogen, Amgen, Eli-Lilly and Merck Sharp & Dohme Corp. Davide Gatti has received speaking fees from Abiogen, Amgen, Eli-Lilly and Neopharmed-Gentili. El Ghoch M, Dalle Grave R, Bazzani PV, Calugi S, Bertoldo F, Braga V declare they have no conflict of interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.